Swiss pharmaceutical giant Novartis has officially commenced construction of its new global biomedical research center in San Diego, California. This facility represents a strategic pillar in the company’s efforts to bolster its drug discovery capabilities within the United States.
Facility Scope and Technological Focus Scheduled for completion in 2029, the facility will span approximately 466,000 square feet and house a workforce of 1,000 employees. The center is designed to support end-to-end drug discovery across several vital therapeutic areas, such as:
-
Oncology and Neuroscience.
-
Regenerative medicine and age-related conditions.
-
Gene, cell, and RNA-based therapies.
-
Integration of advanced AI and computational technologies into pharmaceutical R&D.
A Pillar of the $23 Billion U.S. Investment Plan The San Diego site is a key component of Novartis’ broader $23 billion investment strategy in the U.S. market. This expansive plan integrates research with advanced manufacturing capabilities across multiple states, including:
-
A major manufacturing hub in North Carolina.
-
Radioligand therapy (RLT) production sites in California and Florida.
-
Facility expansions in Indiana, New Jersey, and planned sites in Texas.
Strategic Vision Fiona Marshall, President of Biomedical Research at Novartis, stated that the new center will strengthen the company’s connectivity with its existing global research hubs in Basel (Switzerland) and Cambridge (Massachusetts). By tapping into San Diego’s premier life sciences ecosystem, Novartis aims to accelerate its internal pipeline, ensuring that transformative medicines reach global patients more efficiently.
Source: https://www.pharmaceutical-technology.com/news/novartis-construction-facility-san-diego/?cf-view